Treatment of hypertension in chronic kidney disease
- PMID: 16298269
- DOI: 10.1016/j.semnephrol.2005.05.016
Treatment of hypertension in chronic kidney disease
Abstract
Chronic kidney disease (CKD) is a major public health problem in the United States. It is estimated that nearly 20 million Americans have some degree of chronic kidney disease defined as an estimated glomerular filtration rate of less than sixty milliliters per minute or evidence of kidney damage by imaging study, biopsy, biochemical testing or urine tests with an estimated glomerular filtration rate more than sixty milliliters per minute. Hypertension is present in more than 80% of patients with CKD and contributes to progression of kidney disease toward end stage (ESRD) as well as to cardiovascular events such as heart attack and stroke. In fact the risk for cardiovascular death in this patient population is greater than the risk for progression to ESRD. Proteinuria is an important co-morbidity in hypertensives with CKD and increase risk of disease progression and cardiovascular events. Treatment of hypertension is therefore imperative. The National Kidney Foundation clinical practice guidelines recommend a blood pressure goal of <130 mmHg systolic and <80 mmHg diastolic for all CKD patients. Recent post-hoc analyses of the Modification of Diet in Renal Disease study indicate that lower blood pressure may provide long-term kidney protection in patients with nondiabetic kidney disease. Specifically a mean arterial pressure <92 mmHg (e.g. 120/80 mmHg) as compared to 102-107 mmHg (e.g. 140/90 mmHg) is associated with reduced risk for ESRD. In most cases achieving this goal requires both non-pharmacologic and pharmacologic intervention. Dietary sodium restriction to no more than 2 grams daily is important. In addition, moderate alcohol intake, regular exercise, weight loss in those with a body mass index greater than 25 kg/M(2) and reduced amount of saturated fat help to reduce blood pressure. The first line pharmacologic intervention should be an angiotensin converting enzyme inhibitor or angiotensin II type 1 receptor blocker in those with diabetes or non-diabetics with more than 200 mg protein/gram creatinine on a random urine sample. For non-diabetics with less than 200 mg protein/gram creatinine on a random urine sample, no specific first-line drug class is recommended. After initial dosing with an ACEi, ARB or other drug, a diuretic should be added to the regimen. Thereafter, beta-blockers, calcium channel blockers, apha blockers and alpha 2 agonists (e.g. clonidine) and finally vasodilators (e.g. minoxidil) should be added to achieve blood pressure goal. Combinations of ACEi and ARB are helpful in reducing proteinuria and may also lower blood pressure further in some some cases. Blood pressure should be monitored closely in hypertensive patients with CKD and both clinic and home blood pressure measurements may help the clinician adjust treatment.
Similar articles
-
The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.Can J Cardiol. 2004 Jan;20(1):41-54. Can J Cardiol. 2004. PMID: 14968142
-
[Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].Nefrologia. 2008;28 Suppl 3:39-48. Nefrologia. 2008. PMID: 19018737 Spanish.
-
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).Arch Intern Med. 2005 Apr 25;165(8):936-46. doi: 10.1001/archinte.165.8.936. Arch Intern Med. 2005. PMID: 15851647 Clinical Trial.
-
Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?Clin Ther. 2007 Sep;29(9):1803-24. doi: 10.1016/j.clinthera.2007.09.019. Clin Ther. 2007. PMID: 18035185 Review.
-
New treatment guidelines for a patient with diabetes and hypertension.J Hypertens Suppl. 2003 Mar;21(1):S25-30. J Hypertens Suppl. 2003. PMID: 12769164 Review.
Cited by
-
Biomedical Evaluation of Early Chronic Kidney Disease in the Air Force: Building a Predictive Model from the Taiwan Military Health Service.Bioengineering (Basel). 2024 Feb 28;11(3):231. doi: 10.3390/bioengineering11030231. Bioengineering (Basel). 2024. PMID: 38534505 Free PMC article.
-
Ferroptotic mechanisms and therapeutic targeting of iron metabolism and lipid peroxidation in the kidney.Nat Rev Nephrol. 2023 May;19(5):315-336. doi: 10.1038/s41581-023-00689-x. Epub 2023 Mar 15. Nat Rev Nephrol. 2023. PMID: 36922653 Review.
-
Fluid homeostasis induced by sodium-glucose cotransporter 2 inhibitors: novel insight for better cardio-renal outcomes in chronic kidney disease.Hypertens Res. 2023 May;46(5):1195-1201. doi: 10.1038/s41440-023-01220-2. Epub 2023 Feb 27. Hypertens Res. 2023. PMID: 36849579 Review.
-
Construction and validation of a predictive model for hypocalcemia after parathyroidectomy in patients with secondary hyperparathyroidism.Front Endocrinol (Lausanne). 2022 Nov 30;13:1040264. doi: 10.3389/fendo.2022.1040264. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36531501 Free PMC article. Clinical Trial.
-
A Retrospective Study of the Perioperative Period Management of Joint Arthroplasty in Patients with Chronic Kidney Disease.Orthop Surg. 2023 Feb;15(2):591-605. doi: 10.1111/os.13589. Epub 2022 Dec 1. Orthop Surg. 2023. PMID: 36453119 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical